February 15, 2023
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy
Mechanism of Action/Pathway Profiles
Mechanism of Action Magnifier – 2016 Desk Reference
Welcome to the inaugural edition of our annual Mechanism of Action Magnifierâ„¢! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.
Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets
- Phosphatidylserine (PS) is an immune checkpoint distinct from PD-1/PD-L1, CTLA-4, and other antagonists or agonists of T-cell activation
- Tumors compromise the body’s normal immunosuppressive process of clearance/disposal of dying cells through PS-signaling mechanisms to evade immune detection
- PS exposure in the tumor microenvironment is immunosuppressive and increases in response to chemotherapy and radiation therapy
- Bavituximab is an investigational monoclonal antibody that targets PS and is believed to override PS-mediated immunosuppressive signaling in tumors prevalent in the tumor microenvironment, as well as to provide an immune-activating signal through Fc-γ receptor signaling
Case Presentation: Targeted Therapy in Metastatic Melanoma
The management of melanoma has entered an era of biomarker-driven targeted therapy and immunotherapy. The following case, presented by Sanjiv S. Agarwala, MD, at PMO Live 2015, illustrates the 2015 approach to the management of metastatic melanoma. Case: Metastatic Melanoma A 56-year-old female with a history of T2N2b melanoma and [ Read More ]
Molecular Pathways in Cancer Are Increasingly Being Exploited
Molecular pathways in cancer can be exploited for therapy, and sensitizing genetic aberrations are the ideal targets, said Alex Adjei, MD, PhD, at PMO Live 2015. Cancer cells have to evade a number of stresses to grow. They are complex and live in a toxic environment, but somehow they manage [ Read More ]
Two Cases of Triple-Hit Lymphoma: A Call for Imperative MYC, BCL2, and BCL6 Testing by FISH in Aggressive Lymphomas
Remission in aggressive B-cell lymphomas is increasingly linked to complex karyotypes and gene rearrangements that often portend aggressive behavior and resistance to standard therapy. An understanding of lymphoma cytogenetics has lagged behind that of leukemia, in which pretreatment karyotype constitutes an independent prognostic determinant for attainment of complete remission. In [ Read More ]
Mechanism of Action/Pathway ProfilesConfirming Diagnoses and Identifying Biomarkers Linked to Targeted Treatments with the bioT3 Approach
The current generation of oncologists has witnessed great advances in our understanding of tumor biology and biomarkers linked to treatments. Those advances started with research, but disseminating this information can be difficult given the myriad of obstacles in adoption to practice. The science behind these advances is fascinating and excites [ Read More ]
Interview with the Innovators, Mechanism of Action/Pathway Profiles